GCANRx Announces Completion of Preclinical Study for Neuropsychiatric Cannabinoid Therapy
February 27, 2024 07:45 ET
|
The Greater Cannabis Company, Inc.
BALTIMORE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation...
Global Precision Psychiatry Market Report to 2027 - Increasing Adoption of Inorganic Growth Strategies and Increased Demand for Genomics as Precision Psychiatry Drives Growth
March 23, 2023 05:08 ET
|
Research and Markets
Dublin, March 23, 2023 (GLOBE NEWSWIRE) -- The "Precision Psychiatry Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Biomarkers (Genetic v/s Protein),...
NeuroSigma Announces Promotion of Dr. Colin Kealey to President
January 11, 2022 11:00 ET
|
NeuroSigma, Inc.
LOS ANGELES, Jan. 11, 2022 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a bioelectronic medical device company, today announced the promotion of Dr. Colin Kealey to President. NeuroSigma is the developer...
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leading Next Wave of Psychedelic Drug Development
September 30, 2021 08:30 ET
|
Tryp Therapeutics Inc.
NEW YORK, Sept. 30, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) announces the availability of a broadcast titled, “Investors Turning to Psychedelic...
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Differentiated by Clinical Trials, World-Class Management
July 01, 2021 08:30 ET
|
Tryp Therapeutics Inc.
NEW YORK, July 01, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) announces the availability of a broadcast titled, “GW Pharma Sells for Bilions;...